Suppr超能文献

成人白血病患者接受人类白细胞抗原匹配同胞移植后发生急性移植物抗宿主病的危险因素。

Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.

作者信息

Hahn Theresa, McCarthy Philip L, Zhang Mei-Jie, Wang Dan, Arora Mukta, Frangoul Haydar, Gale Robert Peter, Hale Gregory A, Horan John, Isola Luis, Maziarz Richard T, van Rood Jon J, Gupta Vikas, Halter Joerg, Reddy Vijay, Tiberghien Pierre, Litzow Mark, Anasetti Claudio, Pavletic Stephen, Ringdén Olle

机构信息

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

出版信息

J Clin Oncol. 2008 Dec 10;26(35):5728-34. doi: 10.1200/JCO.2008.17.6545. Epub 2008 Nov 3.

Abstract

PURPOSE

Acute graft-versus-host disease (GVHD) causes substantial morbidity and mortality after human leukocyte antigen (HLA)-identical sibling transplants. No large registry studies of acute GVHD risk factors have been reported in two decades. Risk factors may have changed in this interval as transplant-related techniques have evolved.

PATIENTS AND METHODS

Acute GVHD risk factors were analyzed in 1,960 adults after HLA-identical sibling myeloablative transplant for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or chronic myeloid leukemia (CML) reported by 226 centers worldwide to the Center for International Blood and Marrow Transplant Research from 1995 to 2002. Outcome was measured as time from transplant to onset of grade 2 to 4 acute GVHD, with death without acute GVHD as a competing risk.

RESULTS

Cumulative incidence of grade 2 to 4 acute GVHD was 35% (95% CI, 33% to 37%). In multivariable analyses, factors significantly associated with grade 2 to 4 acute GVHD were cyclophosphamide + total-body irradiation versus busulfan + cyclophosphamide (relative risk [RR] = 1.4; P < .0001), blood cell versus bone marrow grafts in patients age 18 to 39 years (RR = 1.43; P = .0023), recipient age 40 and older versus age 18 to 39 years receiving bone marrow grafts (RR = 1.44; P = .0005), CML versus AML/ALL (RR = 1.35; P = .0003), white/Black versus Asian/Hispanic race (RR = 1.54; P = .0003), Karnofsky performance score less than 90 versus 90 to 100 (RR = 1.27; P = .014), and recipient/donor cytomegalovirus-seronegative versus either positive (RR = 1.20; P = .04). Stratification by disease showed the same significant predictors of grade 2 to 4 acute GVHD for CML; however, KPS and cytomegalovirus serostatus were not significant predictors for AML/ALL.

CONCLUSION

This analysis confirmed several previously reported risk factors for grade 2 to 4 acute GVHD. However, several new factors were identified whereas others are no longer significant. These new data may facilitate individualized risk estimates and raise several interesting biologic questions.

摘要

目的

急性移植物抗宿主病(GVHD)在人类白细胞抗原(HLA)匹配的同胞移植后会导致相当高的发病率和死亡率。二十年来,尚无关于急性GVHD危险因素的大型登记研究报告。在此期间,随着移植相关技术的发展,危险因素可能已经发生了变化。

患者和方法

对1995年至2002年全球226个中心向国际血液和骨髓移植研究中心报告的1960例接受HLA匹配同胞清髓性移植治疗急性髓性白血病(AML)、急性淋巴细胞白血病(ALL)或慢性髓性白血病(CML)的成年患者的急性GVHD危险因素进行分析。观察指标为从移植到2至4级急性GVHD发作的时间,将无急性GVHD死亡作为竞争风险。

结果

2至4级急性GVHD的累积发病率为35%(95%可信区间,33%至37%)。在多变量分析中,与2至4级急性GVHD显著相关的因素有:环磷酰胺+全身照射与白消安+环磷酰胺相比(相对风险[RR]=1.4;P<.0001),18至39岁患者接受血细胞移植与骨髓移植相比(RR=1.43;P=.0023),40岁及以上接受骨髓移植的受者与18至39岁接受骨髓移植的受者相比(RR=1.44;P=.0005),CML与AML/ALL相比(RR=1.35;P=.0003),白人/黑人与亚洲人/西班牙裔种族相比(RR=1.54;P=.0003),卡诺夫斯基表现评分低于90与90至100相比(RR=1.27;P=.014),以及受者/供者巨细胞病毒血清学阴性与阳性相比(RR=1.20;P=.04)。按疾病分层显示,CML中2至4级急性GVHD的显著预测因素相同;然而,KPS和巨细胞病毒血清状态不是AML/ALL的显著预测因素。

结论

该分析证实了先前报道的一些2至4级急性GVHD的危险因素。然而,发现了一些新因素,而其他一些因素不再显著。这些新数据可能有助于进行个体化风险评估,并提出了几个有趣的生物学问题。

相似文献

1
4
HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.
Biol Blood Marrow Transplant. 2011 Jun;17(6):885-92. doi: 10.1016/j.bbmt.2010.09.012. Epub 2010 Sep 24.
9

引用本文的文献

2
Allogeneic Transplantation for Older Adults.
Adv Exp Med Biol. 2025;1475:9-40. doi: 10.1007/978-3-031-84988-6_2.
4
Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.
Methods Mol Biol. 2025;2907:1-56. doi: 10.1007/978-1-0716-4430-0_1.
5
A randomized controlled trial of conventional GVHD prophylaxis with or without teprenone for the prevention of severe acute GVHD.
Ann Hematol. 2025 Mar;104(3):1917-1929. doi: 10.1007/s00277-025-06269-2. Epub 2025 Feb 24.
7
Volumetric modulated arc therapy total body irradiation improves toxicity outcomes compared to 2D total body irradiation.
Front Oncol. 2024 Sep 16;14:1459287. doi: 10.3389/fonc.2024.1459287. eCollection 2024.
8
[Chinese expert consensus on the diagnosis and treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation (2024)].
Zhonghua Xue Ye Xue Za Zhi. 2024 Jun 14;45(6):525-533. doi: 10.3760/cma.j.cn121090-20240608-00214.

本文引用的文献

1
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
Blood. 2008 Oct 15;112(8):3500-7. doi: 10.1182/blood-2008-02-141689. Epub 2008 Jul 29.
4
Differential effect of conditioning regimens on cytokine responses during allogeneic stem cell transplantation.
Bone Marrow Transplant. 2006 Apr;37(7):635-40. doi: 10.1038/sj.bmt.1705295.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验